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Background. The maternal and fetal risk of preg-
nancy after organ transplantation under tacrolimus 
has not been reported. This was prospectively studied 
in 27 pregnancies by 21 female liver recipients who 
were treated with tacrolimus before and throughout 
gestation. 
Method. Twenty-seven babies were born between 
October 1990 and April 1996. In 15 cases, samples were 
obtained at or after delivery and stored (-40°C) for 
comparison of tacrolimus concentration in the mater-
nal blood with different combinations of cord and in-
fant venous blood, breast milk, or a section of the 
placenta. 
Results. The 21 mothers had surprisingly few serious 
complications of pregnancy and no mortality. Two in-
fants with 23 and 24 weeks gestation died shortly after 
birth. The mean birth weight of the other 25 was 
2638±781 g after a gestational period of 36.6±3.3 
weeks. Mean birth weight percentile for gestational 
age was 50.2±26.2 (median 40). On the day of delivery, 
the mean tacrolimus concentrations (ng/ml) were 4.3 
in placenta versus 1.5,0.7, and 0.5 in maternal, cord, 
and child plasma, and 0.6 in the first breast milk spec-
imens. The infants had a 36% incidence of transient 
perinatal hyperkalemia (K+>7.0 meqlL) and a mild 
reversible renal impairment, which were thought to 
reflect in part maternal homeostasis. One newborn 
had unilateral polycystic renal disease (the only 
anomaly). All 25 babies have had satisfactory postna-
tal growth and development with a current mean 
weight percentile of 62±37 (median 80). 
Conclusions. Pregnancy by postliver transplant 
mothers under tacrolimus was possible with a surpris-
ingly low incidence of the hypertension, preeclampsia, 
and other maternal complications historically associ-
ated with such gestations. As in previous experience 
with other immunosuppressive regimens, preterm de-
liveries were common. However, prenatal growth for 
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gestational age and postnatal infant growth for post-
partum age were normal. 
Successful pregnancies have been reported after liver 
transplantation under immune suppression based on aza-
thioprine (1-3), cyclosporine (2-5) and tacrolimus. Although 
the number of reported pregnancies in tacrolimus-treated 
mothers is still small (6, 7), the experience reported herein 
suggests that this will be a frequent event with the wide-
spread use of the new drug. 
In this prospective study of 27 pregnancies in 21 hepatic 
recipients treated with tacrolimus, maternal and fetal events 
were recorded during gestation and afterward. At the time of 
delivery, tacrolimus concentrations were determined in sam-
ples of maternal, infant, and cord blood, and in the placenta 
and breast milk. 
METHODS 
Case Material 
The 27 deliveries occurred between October 1990 and April 1996 
in 21 liver recipients who had undergone transplantation at the 
University of Pittsburgh Medical Center. All but four of the deliver-
ies were in the mothers' cities of residence. The progress of the 
pregnancy and labor as well as results of renal and liver function 
tests, tacrolimus doses, and trough plasma/whole blood concentra-
tions were communicated regularly to the investigators by the pa-
tients, their physicians, and obstetricians. The gestational period 
and the birth weight were recorded in all cases. Percentile intrauter-
ine development was determined with the nomogram of Lubchenco 
et a1. (8), which relates weight to gestational age at birth. The babies 
were followed after birth for a median of 39 months (range 10-76 
months). 
Perinatal Laboratory Studies 
Maternal (n=15), cord (n=13), and infant venous blood, and a 
section of placenta (n=10) were collected at or after the time of 
delivery for determination of tacrolimus concentration. Serial fol-
low-up samples of venous blood were obtained in 7 infants (11 sam-
ples) as well as breast milk from 6 mothers (10 samples). Tacrolimus 
concentrations were assayed in plasma by an ELISA procedure (9) 
until August 1994 and subsequently in whole blood by the micropar-
ticulate enzyme immunoassay method (IMx, Abbott Laboratories, 
Abbott Park, IL) (10), which gives a numerical readout approxi-
mately 10 times higher. The correlation coefficient with the two 
assays is r2 =0.48 (n=101) (our unpublished observation). Placental 
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tacroIimus concentrations were measured by either the ELISA or 
microparticulate enzyme immunoassay method. Renin and aldoste-
rone concentrations in the maternal and cord plasma were measured 
with radioimmunoassay. 
RESULTS 
Maternal 
The mean age of the 21 mothers at the time of the 27 
deliveries was 28.1±5.2 (18.3 to 36.5). Delivery was by Cae-
sarian section in 12 (44%) of the 27 pregnancies, most fre-
quently because of maternal considerations but in several 
cases because of fetal danger (Table 1). 
The full range of original liver diseases is summarized in 
Table 1. The adverse effect of liver failure on fecundity was 
reflected in the pretransplant inability of many patients to 
conceive (n=9) or to complete pregnancies (n=5) (Table 1). 
All 21 women survived their single (n=15) or double (n=6) 
pregnancies. Nineteen of them are still alive and 18 still bear 
the same allografts as during the gestations. Patient 11 was 
noncompliant with immunosuppression throughout the sec-
ond of two successful pregnancies, and underwent successful 
retransplantation for rejection 19 months after the birth of 
her second child. 
The two deaths were not directly related to pregnancy. A 
20-year-old patient (case 7) died 34 months postpartum. She 
conceived within 4 weeks after the primary liver transplan-
tation, developed systemic cytomegalovirus during the first 
trimester of gestation, and gave vaginal birth at 23 weeks to 
a 587-g infant who died 2 hr later. She recovered promptly 
but a subsequent de novo hepatitis C virus infection neces-
sitated retransplantation 30 months later with a 16-week 
survival. A 25-year-old mother (case 12) known for substance 
abuse died of a crack-cocaine overdose 40 months after de-
livery. 
Hepatic allograft function. Although mean liver function 
was little affected (Table 2), there were perturbations during 
(n=4) or after (n=3) 7 of the 27 pregnancies. Anicteric rejec-
tions with transaminase or canalicular enzyme increases 
were observed in patients 4,5, and 6 at 14, 16, and 33 weeks 
of gestation, respectively, and in patients 4 and 8 postpar-
tum. These episodes responded to steroid boluses or modest 
increases in tacrolimus. The only example of chemical jaun-
dice (maximum 2.9 mg/dl) was in pregnancy 11b, and this 
was attributed at the time to recurrent autoimmune hepati-
tis. However, with persistent noncompliance that led to re-
jection subsequent to delivery (and ultimately retransplan-
tation), this earlier diagnosis was suspected to have been 
incorrect. In addition, liver injury tests were transiently el-
evated during systemic cytomegalovirus infection in the first 
trimester of pregnancy 7 and by recrudescent postpartum B 
virus hepatitis in pregnancy 17. 
Immune suppression. The duration of tacrolimus treat-
ment and the interval from transplantation to delivery is 
shown for each patient in Table 1. Twelve of the 21 mothers 
had been switched to tacrolimus from cyclosporine (all before 
conception) because of persistent rejection and/or excessive 
steroid dependence. Prednisone was not given before or dur-
ing 21 of the 27 pregnancies. It was administered during the 
other six pregnancies in daily doses of 5 (n=3), 7.5 (n=2), or 
10 mg/day (n=l). 
Patient 6, who required 48 to 64 mg/day tacrolimus to 
maintain trough plasma concentrations of 0.3-0.5 ng/ml, was 
the only one treated with adjunct azathioprine (50 mg/day). 
With omission of this patient's data, mean doses and trough 
concentrations of tacrolimus before, during, and after the 
trimesters are shown in Table 3. Tacrolimus doses were 
modestly increased during 5 of the 27 pregnancies and de-
creased in 6. 
Renal function. Because tacrolimus dose adjustments 
were made at the first sign of nephrotoxicity, mean blood 
urea nitrogen and creatinine concentrations were stable dur-
ing and after pregnancy (Table 2). Patients 8 and 10 had 
preexisting hypertension, which worsened in the latter case 
and required intensified treatment. New onset hypertension 
occurred in patient 5 during the first trimester and was 
treated for 1 week with methyldopa. Six of the 21 pregnant 
mothers required fludrocortisone to control hyperkalemia. 
Insulin-dependent diabetes mellitus (IDDM*J. Patients 4 
and 10 were insulin-dependent before conception, but the 
second patient had become insulin-free by her second preg-
nancy and subsequently remained insulin-free. There were 
no examples of new IDDM. 
Infections. Patient 1 had a toenail infection during the 
second trimester of her first pregnancy. After her second 
delivery by Caesarian section, she developed wound infection 
and pneumonia. Except for a Salmonella infection during the 
third trimester (patient 4) and cytomegalovirus gastroenter-
itis during the first trimester (patient 7), no other infections 
were recorded. 
Fetal 
Survival. The birth weights of the two infants who died 2 
hr and 2 days after 23 and 24 weeks gestation, respectively, 
were 587 (pregnancy 7) and 510 g (pregnancy lOa). The first 
mother was the one with a serious first trimester cytomega-
lovirus infection. The second, who had a subsequent success-
ful pregnancy (lOb), suffered from progressive hypertension, 
IDDM, and preeclampsia with proteinuria. The remaining 25 
babies are alive and thriving. Except for one example of 
unilateral nonfunctional cystic kidney disease (pregnancy 
14a), none have anomalies. 
Development at birth. Birth weights and gestational peri-
ods for individual infants are shown in Table 1. Fourteen 
(52%) of the 27 babies were premature (gestational period 
<37 weeks) and the remaining 13 (48%) were term babies. 
Mean birth weight percentile for gestational age was 
50.2±26.2 (range <10 to >90; median 40) (8); values are 
depicted for each surviving infant in Figure 1. Thirteen ofthe 
25 were at or below the 40th percentile and 12 were above it. 
The two infants who died were off the Lubchenco scale. 
Current development of newborn babies. The 25 babies 
who survived the perinatal period have been followed until 
January 1997 for a mean of 39±20 months (median 36). 
Their weight for age percentiles, calculated from the Na-
tional Center for Health Statistics percentiles (11), are 
shown in Table 1. Some of the current scores reflect the 
degree of prematurity and low weight at birth. Five of the 25 
babies have percentile growth of :s10, whereas 10 babies 
have percentile growth >95. Both parents of the only infant 
with a current weight <5 percentile (case 1a) are of short 
stature (mother=4'l1", father=5'6"). 
* Abbreviation: IDDM, insulin-dependent diabetes mellitus. 
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TABLE 2. Effect of pregnancy on matemalliver and 
renal functiona 
Liver functionb Renal Functionh 
Bilirubin AST ALT BUN Creatinine 
-----------
Before 
Mean 0.6 32.5 33.2 22 1.3 
SD 0.3 19.5 22.7 8 0.5 
Median 0.6 27 31 21 1.2 
First Trimester 
Mean 0.5 28.7 25.5 18 1.2 
SD 0.1 15.5 12.2 7 0.4 
Median 0.5 26 24 18 1.2 
Second Trimester 
Mean 0.6 30.5 30.5 15 1.1 
SD 0.5 18 25 7 0.4 
Median 0.45 23 23 13.5 1.1 
Third Trimester 
Mean 0.6 28.9 26.5 15 1.2 
SD 0.5 15.3 22.8 9 0.5 
Median 0.4 27 18.5 13 1 
Postpartum 
Mean 0.7 38.3 25.4 20 1.3 
SD 0.4 50.4 21.6 12 0.5 
Median 0.6 25 22.5 15 1.2 
a Abbreviations used in table: ALT, alanine aminotransferase; 
AST, aspartate aminotransferase; BUN, blood urea nitrogen. 
b Values after normalization (see the text). Bilirubin, mg/dl (1 
mg/dl=17 f.LmollL, SI units); ALT, UIL; AST, UIL; creatinine, mg/dl 
(1 mg/dl=88.4 ILmollL, SI units); BUN, mg/dl (1 mg/dl=0.357 f.LmollL, 
SI units). 
TABLE 3. Effect of pregnancy on immunosuppression 
Tacrolimus dosea Tacrolimus levelb 
(mg/day) (ng/m!) 
Before 
Mean 10.3 0.7 
SD 3.3 0.3 
Median 11 0.6 
First Trimester 
Mean 9.7 0.7 
SD 3.3 0.3 
Median 10 0.7 
Second Trimester 
Mean 9.3 0.7 
SD 3.6 0.5 
Median 10 0.5 
Third Trimester 
Mean 10.1 0.5 
SD 3.9 0.3 
Median 10 0.45 
Postpartum 
Mean 9.8 0.8 
SD 4 0.4 
Median 10 0.65 
a Excludes patient 6 with colitis, receiving 48-64 mg/day. 
b Plasma level. 
Perinatal complications. Most of the babies did not need 
unusual care. However, the small infants from pregnancies 
11b and 18 required temporary ventilator support. After 
delivery by Caesarian section (because of fetal distress), the 
child from pregnancy 12 had prolonged hospitalization on 
oxygen. 
Many of the first infants in the series had the postpartum 
sampling shown in Table 4. Elevations in the infants' serum 
creatinine concentration, as well as hyperkalemia, were ob-
served. Except for case 4, these abnormalities resolved spon-
taneously in 24-48 hr. In case 4, Caesarian section was 
performed at 33 weeks for abruptio placentae. The 1712-g 
infant was anuric for 36 hr, but the birth creatinine (3.2 mg, 
Table 4) peaked at 4.8 mg/100 ml and began to decline to 
normal by the third postnatal day. 
Aldosterone and renin concentrations in maternal plasma 
and cord plasma and serum creatinine and potassium in the 
newborn are summarized in Table 4. Because of wide varia-
tions in the aldosterone and renin concentrations, valid cor-
relations could not be made between aldosterone, renin, and 
serum creatinine levels. 
Maternal/fetal and blood brain barriers to tacrolimus. 
The maternal plasma concentrations of tacrolimus at the 
time of delivery and trough levels on subsequent days are 
shown in Table 5. These values exceeded those of cord blood 
in 11 of the 12 pregnancies from which samples were avail-
able. The only exception was in the pregnancy terminated by 
abruptio placentae (case 4), after which the infant had tran-
sient postnatal anuria. The median ratio of the cord plasma 
to maternal plasma concentration was 0.36. 
In four infants, plasma tacrolimus was measured on con-
secutive days. Its rapid decline (cases 3, 4, and 13; Table 5) 
showed the ability of the newborn children to clear the drug. 
The infants were protected from drug toxicity in utero by a 
partial placental barrier. In 9 of 10 placental samples, the 
tacrolimus concentration was 2 to 56 times that in cord blood, 
the only exception being with abruptio placentae (case 4). 
Placental tacrolimus also usually exceeded that of maternal 
plasma (median fourfold). A venous sample from an infant at 
the same time as placental delivery was obtained only in 
pregnancy 14; the placental concentration was seven times 
higher (Table 5). 
In pregnancies 1b and 7, amniotic fluid concentration of 
tacrolimus was <0.2 ng/ml. The cerebrospinal fluid of the 
newborn baby from pregnancy 3 had a tacrolimus concentra-
tion of <0.1 ng/ml (immeasurable). Tacrolimus was present 
in all 10 breast milk samples from 6 mothers at almost half 
the concentration as in contemporaneous maternal samples 
(median ratio was 0.5). 
DISCUSSION 
Pregnancy under azathioprine or cyclosporine-based im-
mune suppression has been a period of maternal and infant 
risk, even under the simpler circumstances of renal trans- ._ 
plantation (12). The 1987 literature compilation by Davison 
(13) of 1569 completed pregnancies in 1009 kidney recipients . 
revealed a 30% incidence of new onset hypertension and/or .-
preeclampsia, significant loss of renal allograft function 
(most commonly caused by serious rejection) in 15% of the 
mothers, and a preterm delivery rate of 45-60% with intra-
uterine growth retardation in at least 20% of all gestations. 
The complication profile was much the same before and after 
the widespread use of cyclosporine (before and after 1983) 
except for more severe hypertension in the later period. Sim-
ilar problems in 154 kidney recipients treated exclusively 
with cyclosporine regimens have been reported from a Preg-
nancy Registry established in Philadelphia in 1991 (14). 
In contrast to the burgeoning pregnancies in the kidney 
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FIGURE 1. (Al Birth weight percen-
tile of the newborn, derived from the 
weight for gestational age nomogram 
of Lubchenco et a1. (8). (B) Gestation 
period in weeks (solid bar) and birth 
weight in grams (striped bar) for each 
newborn baby (*premature baby 
died). 
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TABLE 4. Metabolic studies at the time of delivery 
Plasma Plasma renin 
aldosterone Newborn (Serum) 
Patient (ng/di)a (ng/ml/hr) 
Mother Cord Mother Cord Creatinineb K+ (MEqlL) 
1a 62 43 1.1 10.9 
Ib 8 15 2.8 1.2 1.3 6.8 
2b 11 5 3.2 5.5 
3 8.2 
4 61 32 1.3 3.2 6.1 
5 58 1 4 
6 40 0.9 7 
8 15.4 27.1 5.8 
9 13 15 8.4 17.2 2 7.5 
10 3 4 
11 27 49 6 
12 80 70 7 4 0.8 6.6 
13 28 23 10 8.6 
a Aldosterone, ng/dl (1 ng/dl=0.028 nmollL, SI units). 
b Creatinine, mg/dl (1 mg/dl=88.4 J.LmollL, SI units). 
transplant population, Scantlebury et a1. (2) reported only 20 
pregnancies in 17 patients who had undergone liver trans-
plantation at the University of Colorado (n=3) or University 
of Pittsburgh (n=14) programs between June 1973 and June 
1987. The first four pregnancies were under azathioprine 
immune suppression. The fourth mother permanently dis-
continued both azathioprine and prednisone shortly after 
delivery and remains drug-free 17 years later (15). The last 
16 pregnancies were under cyclosporine-based therapy. The 
complications encountered were similar to those in kidney 
recipients of the two eras, and included an incidence of he-
patic allograft dysfunction that was 37% during pregnancy 
and 53% in the postpartum period. Hypertension, preeclamp-
sia, and premature delivery were common. 
The increase of pregnancies in liver recipients with the 
advent of cyclosporine also was evident in a multicenter 
report 5 years later from the Philadelphia-based National 
Newborn Baby Number 
Cyclosporine Registry (4) summarizing 500 live infant preg-
nancies in 335 women after kidney and extrarenal organ 
transplantation. Thirty-five (7%) of the 500 pregnancies were 
in patients whose liver transplantation was under cyclospo-
rine and two were under tacrolimus, The 35 mothers had a 
high rate of serious hypertension (46%), eclampsia (21%), 
allograft rejection (17%), and graft loss (5.7%) (5). The infants 
tended to be small and premature. 
This historically defined pattern of premature delivery and 
low infant birth weight was similar in the tacrolimus series 
reported herein. Although intrauterine immune suppression 
from any of the drugs used to date may be responsible per se 
for the subnormal fetal growth, it clearly is a reversible effect 
and does not distort embryogenesis unevenly. Two of the 
babies born to liver recipients under azathioprine/cyclospo-
rine are now teenagers, and the first child of the tacrolimus 
era is 6.4 years old. In the tacrolimus babies reported herein, 
there was one (3.8%) nonlethal anomaly (unilateral nonfunc-
tional cystic renal disease). 
Tacrolimus given to the mother is transmitted in signifi-
cant amounts to the fetus despite its concentration in the 
placenta, similar to cyclosporine (16-18). Temporary impair-
ment of the infants' renal function may be caused by tacroli-
mus, as has been previously reported with cyclosporine (19, 
20). However, higher serum creatinine in newborn babies has 
been described after the pregnancies of normal women, and 
in part reflects the maternal creatinine (21,22) as opposed to 
drug damage to the infant kidneys. Similarly, transient post-
natal hyperkalemia due to incomplete maturation ofthe new-
born kidneys' potassium transport is not an unusual finding 
under normal circumstances (23). The obvious risk of adding 
potentially nephrotoxic drugs to these normal perinatal fac-
tors could be perpetuated by allowing the baby access to the 
mother's milk with its high drug content. The hyperkalemia 
caused by tacrolimus has been ascribed in adults to low 
aldosterone and renin levels (24), a hypothesis that could not 
be adequately tested in the present study. 
In contrast to the striking similarities of infant problems 
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TABLE 5. Tacrolimus concentrations in perinatal specimens 
Tacrolimus concentrationa 
Patient Days Colostrum Placenta Cord blood Baby blood delivery Mother blood (ng/ml) (ng/ml) (ng/g) (ng/ml) (ng/ml) 
1a Ob 004 5.6 0.1 
1 0.5 0.4 
2 4.1 1.9 
3 004 
1b 0 3.2 004 
1 1.1 
2b 0 0.5 8.8 
3 0 0.9 004 
1 2.6 1 004 
2 0.7 0.1 
4 0 2.1 1.9 3.1 
1 4.3 104 
2 1.9 0.6 
5 0 2.6 0.2 
1 
2 0.3 0.1 
3 0.3 0.3 0.1 
6 0 3.2 9.3 0.9 
2 1.6 0.4 
7 0 1.2 
8 0 1.6 8.5 0.5 
1 1.3 0.5 
2 2 0.9 
3 1.6 0.6 
9 0 0.8 1.1 004 
1 0.8 004 
2 0.3 0.8 
10 0 2.5 1.6 0.9 
11 0 1.1 0.9 
12 0 2.1 3 
13 0 1.7 0.3 
1 0.6 1.7 
2 004 0.1 
14 0 1.1 (11.3)e 5.9 (58.6)" 0.8 (8A)C 0.8 (8.1)< 
18 0 .6 (6.1)< 0.3 (2.9)C 0.2 (1.7)C 
Mean 1.46 0.79 4.30 0.71 0.54 
SD 1.10 0048 3040 0.77 0.56 
Median 1.15 0.7 2.8 0.4 0.4 
a Except for patients 14 and 18, values of maternal, cord, and baby blood were for plasma, and the plasma method was modified for the 
placenta and colostrum assays. 
b Day O=day of delivery. 
C Plasma estimated concentration is about one tenth of the whole blood or tissue concentration measured by IMx in patients 14 and 18. 
no matter what the baseline immune suppression (azathio-
prine, cyclosporine, and tacrolimus), maternal welfare was 
not commonly perturbed when tacrolimus was used from 
conception to delivery. The low incidence of hypertension, 
preeclampsia, and abnormalities in allograft function com-
pared favorably with our, or any other, reported liver trans-
plant experience. No allograft loss was attributed to preg-
nancy. These improvements are readily explained by 
advantages of tacrolimus versus cyclosporine in our own 
experience (25, 26) and in multicenter randomized trials 
(27-29): better control of rejection, less arterial hypertension, 
and reduced dependence on prednisone. 
It is noteworthy that the two infant losses in the current 
series were by mothers whose conceptions were temporally 
close to liver transplantation. In pregnancy 7, the interven-
ing period was only a few weeks, and in case lOa it was 11.7 
months. In the failed pregnancy of case lOa, preexisting 
hypertension evolved into preeclampsia at a time when ste-
roid weaning was incomplete and while the mother had tem-
porary IDDM. After a 14-month rest and resolution of these 
problems, she conceived again and delivered a viable baby. 
We advise women of childbearing age to avoid pregnancy for 
2 years after liver replacement, and for longer when there are 
(or have been) transplant-related management problems in-
cluding steroid dependence. 
In conclusion, successful pregnancy by postliver transplant 
mothers under tacrolimus was associated with a lower inci-
dence of hypertension and preeclampsia than reported with 
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previous immune suppression regimens, but with a similar 
trend of preterm delivery, low birth weight, and spontane-
ously resolving renal impairment of the infants. 
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